Metformin has recently been shown to have potential to reduce prostate cancer risk. We
conducted a randomized, double-blind, placebo-controlled trial to determine the modulating
effects of metformin on tissue and systemic biomarkers of drug activity and its distribution
into the prostate tissue. Twenty patients with prostate cancer scheduled to undergo
prostatectomy were randomly assigned to receive either extended-release metformin or
placebo for a median of 34 days before surgery. Prostatectomy and serum samples were …